Home | Sitemap | Search | ContactA- A A+
    Public Member Support us  

IBCSG 25-02 / BIG 3-02 (TEXT) 

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

Tamoxifen and Exemestane Trial (TEXT)


please click on the picture to see a larger version

TEXT-Bone Substudy

The TEXT-Bone Substudy investigates serial bone markers for bone remodeling, serial growth factors, and bone mineral density for TEXT patients in selected centers.

Results & Publications



Study Chairs
BIG: Dr. Olivia Pagani - Mendrisio, Switzerland
US Intergroup: Dr. Barbara Walley - Calgary, Canada

Dr. Meredith Regan, Dr. P. Kathryn Gray

Lead Trial Coordinators
Holly Shaw

Data Managers
Karolyn Scott, Monica Greco, Adriana Mora de Karausch

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg24-26_STP@fstrf.org

Date of Activation
August 4, 2003

Date of Closure
March 11, 2011

Targeted Accrual
2639 patients

Final Accrual
2672 patients

Results & Publications Results & Publications
Pathology Pathology


Save the date and join the IBCSG Pink Ladies! June 14, 2020

The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

New publications are available 

All News